Neos Therapeutics, Inc.
NEOS evidence brief
What we can confirm
- BioSniper Score:
- 9.3 / 10
- Lead Asset:
- adzenys er (Approved)
What it means
What to watch
Prepared research question
What matters most for NEOS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
adzenys er (Approved)
Next Catalyst
—
Tracking 5 pipeline candidates · 4 clinical trials · 3 FDA decisions for Neos Therapeutics, Inc..
Run Neos Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Neos Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Neos Therapeutics, Inc.'s lead drug candidate?
Neos Therapeutics, Inc.'s most advanced tracked candidate is adzenys er (Approved) for Treatment of ADHD in patients 6 years and older.
Who is the CEO of Neos Therapeutics, Inc.?
Gerald Mc is the chief executive officer of Neos Therapeutics, Inc. (NEOS).
What therapeutic areas does Neos Therapeutics, Inc. focus on?
Neos Therapeutics, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.